Literature DB >> 28630094

Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice.

David R Gibb1, Jingchun Liu1, Prabitha Natarajan1, Manjula Santhanakrishnan1, David J Madrid2, Stephanie C Eisenbarth1,3, James C Zimring4,5,6, Akiko Iwasaki3,7, Jeanne E Hendrickson8,2.   

Abstract

During RBC transfusion, production of alloantibodies against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatible blood products, resulting in anemia-associated morbidity and mortality. Multiple studies have established that certain inflammatory disorders and inflammatory stimuli promote alloimmune responses to RBC Ags. However, the molecular mechanisms underlying these findings are poorly understood. Type I IFNs (IFN-α/β) are induced in inflammatory conditions associated with increased alloimmunization. By developing a new transgenic murine model, we demonstrate that signaling through the IFN-α/β receptor is required for inflammation-induced alloimmunization. Additionally, mitochondrial antiviral signaling protein-mediated signaling through cytosolic pattern recognition receptors was required for polyinosinic-polycytidylic acid-induced IFN-α/β production and alloimmunization. We further report that IFN-α, in the absence of an adjuvant, is sufficient to induce RBC alloimmunization. These findings raise the possibility that patients with IFN-α/β-mediated conditions, including autoimmunity and viral infections, may have an increased risk of RBC alloimmunization and may benefit from personalized transfusion protocols and/or targeted therapies.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28630094      PMCID: PMC5568771          DOI: 10.4049/jimmunol.1700401

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs.

Authors:  Nicole H Smith; Eldad A Hod; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.

Authors:  Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

3.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

Authors:  Maria Montoya; Giovanna Schiavoni; Fabrizio Mattei; Ion Gresser; Filippo Belardelli; Persephone Borrow; David F Tough
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 4.  Responder individuality in red blood cell alloimmunization.

Authors:  Günther F Körmöczi; Wolfgang R Mayr
Journal:  Transfus Med Hemother       Date:  2014-10-28       Impact factor: 3.747

5.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

6.  Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models.

Authors:  Jin Yu; Susanne Heck; Karina Yazdanbakhsh
Journal:  Am J Hematol       Date:  2007-08       Impact factor: 10.047

7.  Estimating the immunogenicity of blood group antigens: a modified calculation that corrects for transfusion exposures.

Authors:  Gary Stack; Christopher A Tormey
Journal:  Br J Haematol       Date:  2016-06-24       Impact factor: 6.998

Review 8.  The genetics of type I interferon in systemic lupus erythematosus.

Authors:  Paola G Bronson; Christina Chaivorapol; Ward Ortmann; Timothy W Behrens; Robert R Graham
Journal:  Curr Opin Immunol       Date:  2012-08-10       Impact factor: 7.486

Review 9.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

10.  Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Authors:  Michelle Petri; Daniel J Wallace; Alberto Spindler; Vishala Chindalore; Kenneth Kalunian; Eduardo Mysler; C Michael Neuwelt; Gabriel Robbie; Wendy I White; Brandon W Higgs; Yihong Yao; Liangwei Wang; Dominique Ethgen; Warren Greth
Journal:  Arthritis Rheum       Date:  2013-04
View more
  22 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients.

Authors:  Marie Tamagne; Sadaf Pakdaman; Pablo Bartolucci; Anoosha Habibi; Frédéric Galactéros; France Pirenne; Benoît Vingert
Journal:  Blood Adv       Date:  2021-03-09

3.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

4.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

5.  Errors in data interpretation from genetic variation of human analytes.

Authors:  Heather L Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Linda Kapp; Jenna N Lebedev; James C Zimring
Journal:  JCI Insight       Date:  2017-07-06

6.  Differences in Steap3 expression are a mechanism of genetic variation of RBC storage and oxidative damage in mice.

Authors:  Heather L Howie; Ariel M Hay; Karen de Wolski; Hayley Waterman; Jenna Lebedev; Xiaoyun Fu; Rachel Culp-Hill; Angelo D'Alessandro; James D Gorham; Matthew S Ranson; John D Roback; Peter C Thomson; James C Zimring
Journal:  Blood Adv       Date:  2019-08-13

7.  Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease.

Authors:  Raisa Balbuena-Merle; Susanna A Curtis; Lesley Devine; David R Gibb; Matthew S Karafin; Chance John Luckey; Christopher A Tormey; Alexa J Siddon; John D Roberts; Jeanne E Hendrickson
Journal:  Transfusion       Date:  2019-07-29       Impact factor: 3.157

8.  Type 1 IFN signaling critically regulates influenza-induced alloimmunization to transfused KEL RBCs in a murine model.

Authors:  Dong Liu; David R Gibb; Vicente Escamilla-Rivera; Jingchun Liu; Manjula Santhanakrishnan; Zhimin Shi; Lan Xu; Stephanie C Eisenbarth; Jeanne E Hendrickson
Journal:  Transfusion       Date:  2019-08-12       Impact factor: 3.157

9.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

10.  Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease.

Authors:  Yunfeng Liu; Mouli Pal; Weili Bao; Patricia A Shi; Cheryl A Lobo; Xiuli An; Deepa Manwani; Hui Zhong; Karina Yazdanbakhsh
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.